Sitagliptin: Review of preclinical and clinical data regarding incidence of pancreatitis

International Journal of Clinical Practice

Volumn 64, Issue 7, 2010, Pages 984-990

  Engel, S S ^a   Williams Herman, D E ^a   Golm, G T ^a   Clay, R J ^a   MacHotka, S V ^a   Kaufman, K D ^a   Goldstein, B J ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EXENDIN 4; GLIBENCLAMIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIRAGLUTIDE; METFORMIN; PIOGLITAZONE; PLACEBO; ROSIGLITAZONE; SITAGLIPTIN; SULFONYLUREA;

AREA UNDER THE CURVE; CLINICAL TRIAL; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; GENE EXPRESSION PROFILING; HUMAN; HYPERGLYCEMIA; HYPERTRIGLYCERIDEMIA; INCIDENCE; INSULIN RESISTANCE; KIDNEY FAILURE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PANCREATITIS; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; REVIEW; RISK ASSESSMENT;

ACUTE DISEASE; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; HUMANS; HYPOGLYCEMIC AGENTS; PANCREATITIS; PYRAZINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; TRIAZOLES;

EID: 77952692112     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2010.02382.x     Document Type: Review

References (40)

1. Meier JJ, Nauck MA. Glucagon-like peptide 1 (GLP-1) in biology and pathology. Diabetes Metab Res Rev 2005 21: 91 117.
2. Iltz JL, Baker DE, Setter SM et al. Exenatide: an incretin mimetic for the treatment of type 2 diabetes mellitus. Clin Ther 2006 28: 652 665.
3. Drucker DJ. Dipeptidyl peptidase-4 inhibition and the treatment of type 2 diabetes. Diabetes Care 2007 30: 1335 1343.
4. Flock G, Baggio LL, Longnet C et al. Incretin receptors for glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide are essential for the sustained metabolic actions of vildagliptin in mice. Diabetes 2007 56: 3006 3013.
5. Nauck MA, Heimesaat MM, Orskov C et al. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest 1993 91: 301 307.
6. Denker PS, Dimarco PE. Exenatide (exendin-4)-induced pancreatitis: a case report. Diabetes Care 2006 29: 471.
7. Bain SC, Stephens JW. Exenatide and pancreatitis: an update. Expert Opin Drug Saf 2008 7: 643 644.
8. U.S. Food and Drug Administration. Information for Health Care Professionals-Acute Pancreatitis and Sitagliptin (marketed as Januvia or Janumet) [09-25-2009]. http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ DrugSafetyInformationforHealthcareProfessionals/ucm183764.htm (accessed March 2010).
9. Spanier BWM, Dijkgraaf MGW, Bruno MJ. Epidemiology, aetiology and outcome of acute and chronic pancreatitis: an update. Best Pract Res Clin Gastroenterol 2008 22: 45 63.
10. Forsmark CE, Billie J. AGA institute technical review on acute pancreatitis. Gastroenterology 2007 132: 2022 2044.
11. Keech A, Simes RJ, Barter P et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005 366: 1849 1861.
12. Yadov D, Lowenfels AB. Trends in the epidemiology of the first attack of acute pancreatitis: a systematic review. Pancreas 2006 33: 323 330.
13. Noel RA, Braun DK, Patterson RE, Bloomgren GL. Increased risk of acute pancreatitis and biliary disease observed in patients with type 2 diabetes: a retrospective cohort study. Diabetes Care 2009 32: 834 838.
14. Balani AR, Grendell JH. Drug-induced pancreatitis. Drug Saf 2008 31: 823 837.
15. Badalov NS, Baradarian R, Iswara K et al. Drug-induced acute pancreatitis: an evidence-based review. Clin Gastroenterol Hepatol 2007 5: 648 661.
16. Ben MH, Thabet H, Zaghdoudi I et al. Metformin associated acute pancreatitis. Vet Hum Toxicol 2002 44: 47 8.
17. Mallick S. Metformin induced acute pancreatitis precipitated by renal failure. Postgrad Med J 2004 80: 239 240.
18. Fimognari FL, Corsonello A, Pastorell R et al. Metformin-induced pancreatitis: a possible adverse drug effect during acute renal failure. Diabetes Care 2006 29: 1183.
19. Infante JM, Bermejo ABP, Gallardo BP et al. Pancreatitis aguda toxica por metformina sin insuficiencia renal. Med Clin (Barc) 2008 131: 519.
20. Blomgren KB, Sundström A, Steineck G et al. Obesity and treatment of diabetes with glyburide may both be risk factors for acute pancreatitis. Diabetes Care 2002 25: 298 302.
21. Duboeuf T, De Widerspach-Thor A, Scotto B et al. Acute glimepiride-induced pancreatitis. Gastroenterol Clin Biol 2004 28: 409 410.
22. Roblin X, Abinader Y, Baziz A. Acute pancreatitis induced by gliclazide. Gastroenterol Clin Biol 1992 16: 96.
23. Ayoub WA, Kumar AA, Naguib HS et al. Exenatide-induced acute pancreatitis. Endocr Pract 2009 24: 1 16.
24. Tripathy NR, Basha S, Jain R et al. Exenatide and acute pancreatitis. J Assoc Physicians India 2008 56: 987 988.
25. U.S. Food and Drug Administration. Adverse Event Reporting System. http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Surveillance/ AdverseDrugEffects/default.htm (accessed March 2010).
26. Hartnell NR, Wilson JP. Replication of the Weber effect using post-marketing adverse event reports voluntarily submitted to the United States Food and Drug Administration. Pharmacotherapy 2004 24: 743 749.
27. Wysowski DK, Swartz L. Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002: the importance of reporting suspected reactions. Arch Intern Med 2005 165: 1363 1369.
28. Dore DD, Seeger JD, Chan KA. Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide. Curr Med Res Opin 2009 25: 1019 1027.
29. Herrera V, Aubert R, Tully L et al. Pancreatitis in patients treated with exenatide or sitagliptin. ADA Late Breaking Abstracts 2009; p. LB3-4 (#10-LB).
30. MacMahon S, Collins R. Reliable assessment of the effects of treatment on mortality and major morbidity, II: observational studies. Lancet 2001 357: 455 462. (Pubitemid 32156151) (Pubitemid 32156151)
31. Radican L, Rajagopalan S, Mavros P et al. Differences in baseline characteristics between patients prescribed sitagliptin versus exenatide based on a US electronic medical record database. Diabetologia 2009 52 (Suppl. 1 286 287.
32. Zhang Q, Rajagopalan S, Mavros P et al. Baseline characteristics of patients on sitagliptin and other oral antihyperglycemic agents. Diabetes 2009 58 (Suppl. 1 A2222.
33. Data on File.
34. Matveyenko AV, Dry S, Cox HJ et al. Beneficial endocrine but adverse exocrine effects of sitagliptin in the human islet amyloid polypeptide transgenic rat model of type 2 diabetes: interactions with metformin. Diabetes 2009 58: 1604 1615.
35. Luo J, Quan J, Tsai J et al. Nongenetic mouse models of non-insulin-dependent diabetes mellitus. Metabolism 1998 47: 663 668.
36. Mu J, Petrov A, Eiermann GJ et al. Inhibition of DPP-4 with sitagliptin improves glycemic control and restores islet cell mass and function in a rodent model of type 2 diabetes. Eur J Pharm 2009 623: 148 154.
37. Koehler JA, Baggio LL, Lamont BJ et al. Glucagon-like peptide-1 receptor activation modulates pancreatitis-associated gene expression but does not modify the susceptibility to experimental pancreatitis in mice. Diabetes 2009 58: 2148 2161.
38. Nachnani JS, Bulchandani DG, Nookala A et al. Biochemical and histological effects of exendin-4 (exenatide) on the rat pancreas. Diabetologia 2010 53: 153 159.
39. Williams-Herman D, Round E, Swern AS et al. Safety and tolerability of sitagliptin in patients with type 2 diabetes: a pooled analysis. BMC Endocrine Disorders 2008 8: 14.
40. Miettinen O, Nurminen M. Comparative analysis of two rates. Stat Med 1985 4: 213 226.